Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$56.30 USD
+1.37 (2.49%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $56.26 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 61 - 80 ( 310 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
KOLs? Perspective on Cardiac Myosin Inhibitors in oHCM; All Eyes on REDWOOD-HCM Imminent Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Gains the Spotlight Among Therapies For Patients With Severe HF at ACC.21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Key Progress Across All Programs Sets Milestones for 2H21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
REDWOOD-HCM Expands With Cohort 3; All Eyes on CK-274''s Results in Mid-2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CK-274?s Promising PK/PD Profile Emerges at ASC?21 With Key Differentiation to Comps
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2020 Results; Critical Visibility from FDA Soon for Omecamtiv; CK-274 Should Continue to Differentiate in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Vericiguat FDA Approval Signals a Plausible Path for Omecamtiv; Target Increased to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Busy Year Ahead for Assets Across The Pipeline; Path Forward for Omecamtiv to be Defined
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Cytokinetics Regains Freedom to Operate Worldwide With Omecamtiv in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CK-274 Moves Forward in REDWOOD-HCM as Expected
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Continues to Delineate Promising Target Population; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Looks for Future Without Amgen; Need FDA''s Views; Target Reduced to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Significant Signal Points to Clinical Benefits in More Than 50% Pre-Specified Population; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q20 Results; GALACTIC-HF Data at AHA Set to Define Omecamtiv''s Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
GALACTIC-HF Primary Hits; Many Open Questions Though Until AHA; Target Reduced to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
COSMIC-HF Adds Another Feather to Omecamtiv?s Cap; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Speculation Fire Gets More Gasoline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CK-271 Enters the Clinic as Planned While Omecamtiv?s Prime Time Is Approaching
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q20 Results; Cardiac Programs Set to Impress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Prepped for Success; Let''s Get Real About Numbers; Target Increased to $
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J